Department of Experimental Immunohaematology, Sanquin Research, Amsterdam, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam.
Br J Haematol. 2010 Feb;148(3):428-40. doi: 10.1111/j.1365-2141.2009.07960.x. Epub 2009 Oct 22.
Mesenchymal stromal cells (MSC) are potential cells for cellular therapies, in which the recruitment and migration of MSC towards injured tissue is crucial. Our data show that culture-expanded MSC from fetal lung and bone marrow, adult bone marrow and adipose tissue contained a small percentage of migrating cells in vitro, but the optimal stimulus was different. Overall, fetal lung-MSC had the highest migratory capacity. As fetal bone marrow-MSC had lower migratory potential than fetal lung-MSC, the tissue of origin may determine the migratory capacity of MSC. No additive effect in migration towards combined stimuli was observed, which suggests only one migratory MSC fraction. Interestingly, actin rearrangement and increased paxillin phosphorylation were observed in most MSC upon stromal cell-derived factor-1alpha or platelet-derived growth factor-BB stimulation, indicating that this mechanism involved in responding to migratory cues is not restricted to migratory MSC. Migratory MSC maintained differentiation and migration potential, and contained significantly less cells in S- and G2/M-phase than their non-migrating counterpart. In conclusion, our results suggest that MSC from various sources have different migratory capacities, depending on the tissue of origin. Similar to haematopoietic stem cells, cell cycle contributes to MSC migration, which offers perspectives for modulation of MSC to enhance efficacy of future cellular therapies.
间质基质细胞(MSC)是细胞治疗的潜在细胞,MSC 向损伤组织的募集和迁移是至关重要的。我们的数据表明,来自胎儿肺和骨髓、成人骨髓和脂肪组织的培养扩增的 MSC 在体外含有一小部分迁移细胞,但最佳刺激因素不同。总体而言,胎儿肺-MSC 具有最高的迁移能力。由于胎儿骨髓-MSC 的迁移潜力低于胎儿肺-MSC,因此组织起源可能决定 MSC 的迁移能力。对联合刺激的迁移没有观察到相加效应,这表明只有一个迁移 MSC 亚群。有趣的是,在基质细胞衍生因子-1α或血小板衍生生长因子-BB 刺激下,大多数 MSC 中观察到肌动蛋白重排和黏着斑蛋白磷酸化增加,表明这种参与响应迁移线索的机制不仅限于迁移 MSC。迁移 MSC 保持分化和迁移能力,并且 S 期和 G2/M 期的细胞数量明显少于非迁移 MSC。总之,我们的结果表明,来自不同来源的 MSC 具有不同的迁移能力,这取决于组织起源。与造血干细胞类似,细胞周期有助于 MSC 的迁移,这为调节 MSC 以增强未来细胞治疗的疗效提供了新的思路。